Lbmc Investment Advisors LLC Makes New $207,000 Investment in PerkinElmer, Inc. (NYSE:PKI)

Lbmc Investment Advisors LLC bought a new position in shares of PerkinElmer, Inc. (NYSE:PKI) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,133 shares of the medical research company’s stock, valued at approximately $207,000.

A number of other large investors have also recently bought and sold shares of PKI. Hudson Valley Investment Advisors Inc. ADV raised its holdings in shares of PerkinElmer by 0.6% in the fourth quarter. Hudson Valley Investment Advisors Inc. ADV now owns 19,851 shares of the medical research company’s stock valued at $1,928,000 after buying an additional 121 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of PerkinElmer by 16.4% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 950 shares of the medical research company’s stock worth $80,000 after purchasing an additional 134 shares in the last quarter. NEXT Financial Group Inc boosted its position in shares of PerkinElmer by 75.0% during the 4th quarter. NEXT Financial Group Inc now owns 350 shares of the medical research company’s stock worth $34,000 after purchasing an additional 150 shares in the last quarter. IFM Investors Pty Ltd grew its stake in shares of PerkinElmer by 1.6% during the 4th quarter. IFM Investors Pty Ltd now owns 10,791 shares of the medical research company’s stock worth $1,048,000 after purchasing an additional 168 shares during the period. Finally, Equitable Trust Co. grew its stake in shares of PerkinElmer by 5.2% during the 2nd quarter. Equitable Trust Co. now owns 3,667 shares of the medical research company’s stock worth $354,000 after purchasing an additional 180 shares during the period. Institutional investors own 95.74% of the company’s stock.

In other news, Director Pascale Witz sold 1,043 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $90.67, for a total value of $94,568.81. Following the completion of the transaction, the director now owns 2,446 shares of the company’s stock, valued at $221,778.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Andrew Okun sold 11,984 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $94.12, for a total transaction of $1,127,934.08. Insiders own 1.80% of the company’s stock.

PKI has been the topic of a number of research analyst reports. UBS Group decreased their price objective on shares of PerkinElmer from $101.00 to $92.00 and set a “neutral” rating on the stock in a report on Friday, October 18th. Wells Fargo & Co started coverage on shares of PerkinElmer in a report on Tuesday, January 7th. They issued an “equal weight” rating and a $105.00 target price for the company. Piper Jaffray Companies cut shares of PerkinElmer from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $104.00 to $89.00 in a report on Thursday, October 31st. Raymond James reiterated an “average” rating and set a $51.00 price target on shares of PerkinElmer in a research report on Tuesday, November 5th. Finally, Bank of America raised PerkinElmer from a “neutral” rating to a “buy” rating and set a $105.00 price target on the stock in a research note on Thursday, September 26th. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. PerkinElmer currently has a consensus rating of “Hold” and an average price target of $84.79.

NYSE:PKI traded down $0.52 during mid-day trading on Wednesday, hitting $100.82. 585,279 shares of the company’s stock traded hands, compared to its average volume of 579,277. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.30. The firm’s 50 day simple moving average is $97.22 and its 200 day simple moving average is $89.63. PerkinElmer, Inc. has a 1 year low of $78.35 and a 1 year high of $103.00. The company has a market cap of $11.26 billion, a PE ratio of 48.01, a price-to-earnings-growth ratio of 1.75 and a beta of 1.30.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.05. The company had revenue of $706.92 million for the quarter, compared to the consensus estimate of $722.69 million. PerkinElmer had a net margin of 8.27% and a return on equity of 16.45%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.90 earnings per share. On average, research analysts expect that PerkinElmer, Inc. will post 4.08 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, January 16th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. PerkinElmer’s dividend payout ratio (DPR) is 7.76%.

PerkinElmer Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Story: What are gap-down stocks?

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.